Abstract
In the early 90s, Schering1 divested two non-pharmaceutical divisions and bought a third division, its plant protection business, into an independent joint-venture firm with Hoechst AG/Germany.
This case study has been authored by Dr. Bernd Müller, Ph Project Coordination, Biology Research, Schering AG. This case study was written in 1998: The reader should keep in mind that all numbers, figures, organization charts and forecasts represent the state of 1998 or before. The case study was revised in 2007 by Alexander Schicker.
As a result of the take-over by Bayer, Schering AG was renamed Bayer Schering Pharma AG in December 2006.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2008). Schering: Synchronized Drug Development. In: Managing Global Innovation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68952-2_17
Download citation
DOI: https://doi.org/10.1007/978-3-540-68952-2_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-25441-6
Online ISBN: 978-3-540-68952-2
eBook Packages: Business and EconomicsBusiness and Management (R0)